Financial reports
ARS
2023 FY
Annual report to shareholders
10 Apr 24
10-K
2023 FY
Annual report
14 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
29 Mar 23
10-K
2022 FY
Annual report
21 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
Current reports
8-K
Entry into a Material Definitive Agreement
25 Mar 24
8-K
Departure of Directors or Certain Officers
21 Mar 24
8-K
Other Events
18 Mar 24
8-K
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Feb 24
8-K
Unregistered Sales of Equity Securities
14 Feb 24
8-K
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
9 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
29 Nov 23
8-K
Other Events
27 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Nov 23
Registration and prospectus
424B3
Prospectus supplement
25 Mar 24
POS EX
Additional exhibits for listing
14 Mar 24
424B3
Prospectus supplement
14 Mar 24
424B4
Prospectus supplement with pricing info
9 Feb 24
S-1/A
IPO registration (amended)
8 Feb 24
S-1/A
IPO registration (amended)
10 Jan 24
S-1/A
IPO registration (amended)
4 Jan 24
S-1/A
IPO registration (amended)
19 Dec 23
S-1/A
IPO registration (amended)
15 Dec 23
S-1
IPO registration
9 Nov 23
Proxies
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
PRE 14A
Preliminary proxy
29 Mar 24
DEF 14A
Definitive proxy
29 Mar 23
DEFA14A
Additional proxy soliciting materials
29 Mar 23
PRE 14A
Preliminary proxy
17 Mar 23
DEFA14A
Additional proxy soliciting materials
15 Mar 22
DEFA14A
Additional proxy soliciting materials
15 Mar 22
DEF 14A
Definitive proxy
15 Mar 22
PRE 14A
Preliminary proxy
4 Mar 22
Other
EFFECT
Notice of effectiveness
9 Feb 24
CORRESP
Correspondence with SEC
7 Feb 24
CORRESP
Correspondence with SEC
7 Feb 24
CORRESP
Correspondence with SEC
17 Jan 24
CORRESP
Correspondence with SEC
17 Jan 24
CORRESP
Correspondence with SEC
16 Jan 24
CORRESP
Correspondence with SEC
16 Jan 24
CORRESP
Correspondence with SEC
11 Jan 24
CORRESP
Correspondence with SEC
11 Jan 24
CORRESP
Correspondence with SEC
5 Jan 24
Ownership
SC 13G
LYTTON LAURENCE W
13 Mar 24
SC 13G
Bleichroeder LP
11 Mar 24
SC 13G
Altium Capital Management LP
20 Feb 24
SC 13G
HIRSCHMAN ORIN
13 Feb 24
4
KENNETH J WIDDER
11 May 23
4
VICKIE S REED
11 May 23
4
Malcolm R Hill
11 May 23
4
CAM L GARNER
11 May 23
4
Todd C Brady
11 May 23
4
David A Gonyer
10 Feb 23